Oncogenic MET gene fusions occur only in about 0.3% of lung cancer patients and have been reported with multiple gene partners, such as CAV1, CD74, KIF5B, and HLA-DRB1, among others.9 In these oncogenic fusions, MET is typically the 3ʹ partner, leading to in-frame fusions with preserved kinase domains. The gene discussed is MET; the disease is lung carcinoma.